- RecruitingTherapeutic exploratory (Phase II)
C1071003 - MAGNETISMM-3, An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One Proteasome Inhibitor, One Immunomodulatory Drug and One Anti-CD38 Antibody
This clinical trial is testing a new medicine called elranatamab for adults with multiple myeloma. It is designed for people whose cancer has returned or stopped responding after trying three standard types of treatment. The aim is to find out how well the drug works on its own.
For: Multiple myelomaBelgium · Poland · France - Active not recruitingPHASE3
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
This study is for people with newly diagnosed multiple myeloma who have had a stem cell transplant. It compares a new medicine called elranatamab with a standard treatment, lenalidomide, to see which works better at keeping the cancer under control. It will last about five years.
For: Multiple MyelomaUnited States · Australia · Austria - RecruitingPHASE3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
This study looks at new ways to treat multiple myeloma. Researchers are testing a drug called elranatamab, alone and with daratumumab, against a standard treatment. The aim is to find better and safer treatments for people who have tried other medicines.
For: Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
This study compares two treatments for newly diagnosed multiple myeloma in adults who can't have a stem cell transplant. It aims to see if a combination including Elranatamab is better than another standard combination at controlling the cancer and improving patients' lives.
For: Multiple MyelomaUnited States · Australia · Austria - RecruitingPHASE1
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
This study is looking at an experimental treatment for multiple myeloma that has come back or hasn't responded to other treatments. It combines two medicines, elranatamab and iberdomide, to see how safe and effective they are together in adults.
For: Multiple MyelomaUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
For: Haematological Malignancy · Acute Myeloid Leukemia · Non Hodgkin LymphomaUnited States · France · Spain - RecruitingPHASE2
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
This study is looking at a new drug called Elranatamab for people with a condition called 'high-risk smoldering multiple myeloma'. We want to see how well it works and if it's safe to use in people who haven't had treatment before.
For: Smoldering Multiple MyelomaFinland · France · Greece - RecruitingPHASE1, PHASE2
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
This study is for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It's testing a new combination of medicines, mezigdomide and elranatamab, to see if they are safe, what dose works best, and how well they might treat the cancer.
For: Multiple MyelomaUnited States · Canada · China - Not yet recruitingPHASE2
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
This study compares two treatments, Elranatamab with Lenalidomide, and Daratumumab with Lenalidomide, for people with newly diagnosed advanced blood cancer called multiple myeloma, after they've had a stem cell transplant. It aims to see which treatment works best to keep the cancer from coming back.
For: Multiple MyelomaFrance - RecruitingPHASE4
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
This study is for people with multiple myeloma who are already taking elranatamab in a previous study and benefiting from it. It allows them to continue getting the medicine if it's helping them.
For: Multiple MyelomaUnited States · Australia · Canada - AuthorisedTherapeutic confirmatory (Phase III)
C1071015 - ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
This study is for people with multiple myeloma who are already taking the drug elranatamab as part of another Pfizer study. It helps them keep getting the treatment after their first study finishes. Doctors are watching for any side effects.
For: Multiple myelomaFrance · Spain · Germany - RecruitingPHASE3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
This study is testing a new medicine called elranatamab for people with a type of blood cancer called multiple myeloma. It's for those whose cancer has returned after other treatments. We want to see if elranatamab works better than standard medicines.
For: Multiple MyelomaUnited States · Argentina · Australia